PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-c...
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
About this item
Full title
Author / Creator
Chia, Stephen K L , Martin, Miguel , Holmes, Frankie A , Ejlertsen, Bent , Delaloge, Suzette , Moy, Beverly , Iwata, Hiroji , von Minckwitz, Gunter , Mansi, Janine , Barrios, Carlos H , Gnant, Michael , Tomašević, Zorica , Denduluri, Neelima , Šeparović, Robert , Kim, Sung-Bae , Jakobsen, Erik Hugger , Harvey, Vernon , Robert, Nicholas , Smith, 2nd, John , Harker, Graydon , Zhang, Bo , Eli, Lisa D , Ye, Yining , Lalani, Alshad S , Buyse, Marc and Chan, Arlene
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free survival (iDFS) in women who completed trastuzumab-based adjuvant therapy for early breast cancer (EBC). We asse...
Alternative Titles
Full title
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
Authors, Artists and Contributors
Author / Creator
Martin, Miguel
Holmes, Frankie A
Ejlertsen, Bent
Delaloge, Suzette
Moy, Beverly
Iwata, Hiroji
von Minckwitz, Gunter
Mansi, Janine
Barrios, Carlos H
Gnant, Michael
Tomašević, Zorica
Denduluri, Neelima
Šeparović, Robert
Kim, Sung-Bae
Jakobsen, Erik Hugger
Harvey, Vernon
Robert, Nicholas
Smith, 2nd, John
Harker, Graydon
Zhang, Bo
Eli, Lisa D
Ye, Yining
Lalani, Alshad S
Buyse, Marc
Chan, Arlene
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_cf5037433d854254a48613d85af66f77
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cf5037433d854254a48613d85af66f77
Other Identifiers
ISSN
1465-542X,1465-5411
E-ISSN
1465-542X
DOI
10.1186/s13058-019-1115-2
